Drug Trial Radar · NCT04510207
A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
Last checked: Nov 20, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44,101
Actual
Start
Jul 16, 2020
Primary completion
Jun 16, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- China National Biotec Group Company LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- G42 Healthcare Research Technology Projects LLC; Abu Dhabi Health Services Company; Wuhan Institute of Biological Products Co., Ltd; Beijing Institute of Biological Products Co Ltd.
- First posted
- Aug 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.
Conditions
- COVID-19
Interventions
Inactivated SARS-CoV-2 Vaccine (Vero cell)Biological
The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
Inactivated SARS-CoV-2 Vaccine (Vero cell)Biological
The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP
PlaceboBiological
The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of COVID-19 cases after two-doses of vaccinationTime frame: From14 days after the second dose to 6 month after the second dose
- The incidence of COVID-19 cases after the booster dose of immunizationTime frame: From 14 days after the booster dose
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
Bahrain International Exhibition & Convention Centre Affiliated to Salymynia Medical Complex S
Sanābis, Bahrain
Katameya Medical Center
Cairo, Egypt
Vacsera health Care facilities , MoH
Cairo, Egypt
Prince Hamza Hospital
Amman, Jordan
Sheikh Khalifa Medical City, SEHA
Abu Dhabi, United Arab Emirates
Al Qarain Primary Health Care Centre-MOHAP
Sharjah city, United Arab Emirates
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.